samedan logo
 
 
spacer
home > white papers > Personalised Medicine - Pharma and Dx Firms Share Wider Horizons - DiagnostikNet-BB
WHITE PAPERS
logo_Diagnostiki.jpg

DiagnostikNet-BB

phone +49 (0) 3302 55 199-14
email f.adams@diagnostiknet-bb.de
web http://www.diagnostiknet-bb.de
email Neuendorfstraße 17/ 16761 Hennigsdorf

Personalised Medicine - Pharma and Dx Firms Share Wider Horizons

Personalised medicine might be a popular catch-phrase at the moment, but the term often causes confusion, as there is still no uniform definition for it. The expression can include areas as diverse as the measurement of individual risk, early detection using biomarker testing, stratification of patients suffering from a disease and predictions about its course.
Personalised Medicine - Pharma and Dx Firms Share Wider Horizons
spacer

Member login

E-mail address:

Password:
Remember me


News and Press Releases

GlycoSeLect and IonDx Inc., Collaborating on High-throughput Glycoprotein Analyses

GlycoSeLect Ltd and IonDx Inc., are actively engaged in a research collaboration to evaluate the use of Recombinant Prokaryotic Lectins RPLs and IonDx’s Ion Mobility Spectrometry technology as a new way to screen glycoproteins rapidly. “GlycoSeLect’s glycan specific lectins provide a high degree of specificity that will improve detection, monitoring and profiling of glycosylation within a wide range of biotherapeutics. Hence, we are excited to join GlycoSeLect and apply our ion mobility technology to all phases of biotherapeutic production and help manufacturers streamline this analytical bottleneck”, said Ms. Ananya Dubey Kelsoe, Executive Director of Business and Corporate Development at IonDx Inc.,
More info >>


White Papers

Driving ROI: The Case for Investing in Contract & Site Regulatory Document Management Services

DrugDev

With tight timelines and complicated regulatory documentation requirements, getting a clinical trial up and running quickly is easier said than done. Key milestones can be achieved only after the successful negotiation of clinical trial agreements and completion of essential regulatory documents. Many clinical trials are hindered by inefficient, labor-intensive processes. Prolonged, inefficient activation can hamper investigator satisfaction and, ultimately, have a negative bottom-line impact for sponsors and CROs. In addition, the Sunshine Act is heightening the importance of financial disclosure in clinical trials. Without a robust financial disclosure strategy, sponsors cannot ensure that physician self-reported financial disclosure data are aligned with the payment data being reported through the Sunshine Act, increasing financial and regulatory risk.
More info >>


Industry Events

12th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology

8-11 February 2021, Vienna, Austria

In continuation of the very successful scientific meetings in Budapest, Paris, Berlin, Florence, Geneva, Barcelona, Malta, Istanbul, Lisbon, Glasgow and Granada, the 12th PBP World will be held in Vienna from 8-11 Feb 2021. This every two year held conference has gained an ever increasing impact among the pharmaceutical scientists: With up to 1000 submitted abstracts and about 1300 participants it has become a well-established major meeting, attracting scientists from all over the world.
More info >>


©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement